ImmuCell Corporation
ICCC Healthcare Biotechnology
ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024. In the quarter to June 2026, revenue grew 11.5%, EPS grew 233.3%, free cash flow grew 54.9% and total debt fell 15.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ICCC
ImmuCell Corporation (ICCC) P/E ratio
As of 16 October 2026, ImmuCell Corporation (ICCC) trades at a P/E ratio of 126×. Over the past ten years it has ranged from 0.0× (June 2026) to 1,444× (August 2022); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 43.2× | 129.06% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 119× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 23.6× | (35.52%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| ANIX ANIXA BIOSCIENCES INC compare | n/m |
| RANI Rani Therapeutics Holdings, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| CBUS Cibus, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| ICCC ImmuCell Corporation | 126× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)